CD274 and neoplasm: Unlike other anti-CD274 mAbs which are designed to eliminate any ADCC/CDC activity as a precaution of off-tumor cytotoxicity, the IgG1-Fc region of avelumab binds to FcγRs on NK cells and directly mediates cellular cytotoxicity against tumor cells (40).